In vitro activity of azithromycin compared with that of erythromycin against Actinobacillus actinomycetemcomitans.
The in vitro susceptibility of Actinobacillus actinomycetemcomitans to azithromycin, a new macrolide antibiotic of a new class known as azalides, was compared with that of erythromycin by the agar dilution method on Mueller-Hinton Haemophilus test medium. Eighty-two A. actinomycetemcomitans strains, 79 recent clinical isolates obtained from 40 periodontally healthy or diseased subjects, and 3 type strains were included in the study. Erythromycin showed poor in vitro activity against A. actinomycetemcomitans. Azithromycin, however, was highly effective against A. actinomycetemcomitans: all strains were inhibited at 2.0 micrograms/ml. Azithromycin exhibited the best in vitro activity against the serotype a subpopulation of A. actinomycetemcomitans: 100% of the strains were inhibited at 1.0 micrograms/ml. The lowest MICs were, however, recorded by serotype b strains. Since azithromycin has favorable pharmacokinetic properties, including excellent distribution into tissues, it could be expected to pass into gingival crevicular fluid at levels sufficient to inhibit A. actinomycetemcomitans in vivo. Therefore, it is a good candidate for future clinical trials in A. actinomycetemcomitans-associated periodontitis.
Pajukanta
R
R
Department of Periodontology, University of Helsinki, Finland.
Asikainen
S
S
Saarela
M
M
Alaluusua
S
S
Jousimies-Somer
H
H
D000188:Actinobacillus / Q000187:drug effects*; D000189:Actinobacillus Infections / Q000382:microbiology; D017963:Azithromycin; D015169:Colony Count, Microbial; D004917:Erythromycin / Q000031:analogs & derivatives* / Q000494:pharmacology*
D004917:Erythromycin; D017963:Azithromycin